Progress of bispecific antibodies in treatment of multiple myeloma
10.3760/cma.j.cn115356-20230102-00002
- VernacularTitle:双特异性抗体治疗多发性骨髓瘤研究进展
- Author:
Lingna LI
1
;
Gang AN
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所） 实验血液学国家重点实验室 国家血液系统疾病临床医学研究中心 细胞生态海河实验室，天津 300020
- Keywords:
Multiple myeloma;
Immunotherapy;
Bispecific antibody
- From:
Journal of Leukemia & Lymphoma
2023;32(4):199-202
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma is a malignant disorder of plasma cells. Although the prognosis of MM patients has improved significantly with the widespread use of new targeted drugs such as immunomodulators, proteasome inhibitors and autologous hematopoietic stem cell transplantation, the disease will eventually recur and progress. In recent years, immunotherapy has made breakthroughs in the treatment of MM, chimeric antigen receptor T-cell therapy, antibody conjugate drugs and bispecific antibodies have shown significant effectiveness and good safety at different stages of the disease. Bispecific antibodies, which bind both CD3 on T cells and target molecules on the surface of malignant plasma cells, are effective immunotherapeutic agents for patients with relapsed/refractory MM. This article reviews the research progress of bispecific antibodies in the treatment of MM in conjunction with the reports at the 64th American Society of Hematology Annual Meeting.
